<DOC>
	<DOCNO>NCT02704429</DOCNO>
	<brief_summary>Open-label cohort study adult patient newly diagnose relapse pemphigus vulgaris , intra-patient dose-adjustment base clinical response BTK occupancy , conventional immunosuppressive `` rescue treatment '' , indicate . The duration therapy 12 week , follow 12 week follow .</brief_summary>
	<brief_title>A Study PRN1008 Adult Patients With Pemphigus Vulgaris</brief_title>
	<detailed_description>Primary Objectives : To evaluate safety PRN1008 patient pemphigus vulgaris ( PV ) To evaluate clinical activity PRN1008 patient PV , per criterion European Academy Dermatology Venereology ( EADV ) 2014 Pemphigus S2 Guideline ( Hertl et al . 2015 ) Secondary Objectives To evaluate pharmacokinetics ( PK ) pharmacodynamics ( PD ) multiple dos PRN1008 patient PV To evaluate relationship PK PD efficacy safety patient population</detailed_description>
	<mesh_term>Pemphigus</mesh_term>
	<criteria>Male female patient , age 18 80 year old , biopsyproven , mildmoderate PV ( PDAI 8 45 ) either : newly diagnose patient ( i.e . naïve effective induction treatment regimen ) initial period PRN1008 monotherapy judge clinically acceptable , relapse patient , initial period PRN1008 monotherapy , combination therapy low dose corticosteroid ( ≤ 10 mg/day ) , azathioprine , mycophenolate mofetil , sulfasalazine dapsone , judge clinically acceptable , provided cessation azathioprine , mycophenolate mofetil , sulfasalazine , dapsone within two four week anticipate Pregnant lactate woman A history malignancy type , surgically excise nonmelanoma skin cancer situ cervical cancer within 5 year day dose Use immunologic response modifier follow period prior Day 1 : 1 week : cyclophosphamide ; 4 week : Kinaret ( anakinra ) Enbrel ( etanercept ) ; 12 week : Remicade ( infliximab ) , Humira ( adalimumab ) , Simponi ( golimumab ) , Orencia ( abatacept ) , Actemra ( tocilizumab ) , Cimzia ( certolizumab ) , Cosentyx ( secukinumab ) , intravenous immunoglobulin , plasmapheresis ; 6 month : Rituxan/MabThera ( rituximab ) , ofatumumab , antiCD20 antibody Use &gt; 10 mg per day oral prednisolone 1 week within 4 week prior Day 1 ( inhale mucosal [ symptomatic treatment oral lesion ] corticosteroid allow ) Has receive investigational drug ( currently use investigational device ) within 30 day receive first dose study medication , least 5 time respective elimination halflife time ( whichever longer ) Donation unit blood blood product within 4 week prior Day 1 History solid organ transplant Positive screening HIV , hepatitis B ( surface core antibody unrelated vaccination ) , hepatitis C ( antiHCV antibody confirm Hep C RNA ) History active latent tuberculosis ( TB ) infection ( subject must also test negative use QuantiFERON® test eligible study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>